Payment overview · 2025
General Payments
$322.90
19 reported records · 6 companies
Healthcare provider profile · identity verified
Mark Anthony Vice, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BENTON, AR · NPI 1134188063
Verified facts
What the public records show
CMS Open Payments records show Mark Anthony Vice, M.D. received $322.90 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.31 | 49.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.83 | 14.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.64 | 12.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.98 | 9.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.34 | 8.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.80 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $322.90 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $108.41 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $108.41 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.90 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.90 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.90 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.83 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.34 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1047 | 209 |
| Levothyroxine Sodium | Levothyroxine Sodium | 634 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 443 | 81 |
| Omeprazole | Omeprazole | 385 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 84 |
| Gabapentin | Gabapentin | 344 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 71 |
| Metformin Hcl | Metformin Hcl | 283 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 265 | 47 |
| Potassium Chloride | Potassium Chloride | 261 | 58 |
| Simvastatin | Simvastatin | 236 | 50 |
| Trazodone Hcl | Trazodone Hcl | 227 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 41 |
| Alprazolam | Alprazolam | 207 | 29 |
| Meloxicam | Meloxicam | 207 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 40 |
| Glimepiride | Glimepiride | 204 | 33 |
| Lisinopril | Lisinopril | 193 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 39 |
| Losartan Potassium | Losartan Potassium | 169 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 37 |
| Tramadol Hcl | Tramadol Hcl | 159 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 156 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 138 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 25 |
| Atenolol | Atenolol | 117 | 26 |
| Prednisone | Prednisone | 115 | 92 |
| Allopurinol | Allopurinol | 114 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 16 |
| Sertraline Hcl | Sertraline Hcl | 107 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 86 |
| Bupropion Xl | Bupropion Hcl | 102 | 24 |
| Ezetimibe | Ezetimibe | 91 | 20 |
| Furosemide | Furosemide | 89 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 84 | 17 |
| Celecoxib | Celecoxib | 84 | 20 |
| Buspirone Hcl | Buspirone Hcl | 83 | 16 |
| Carvedilol | Carvedilol | 83 | 17 |
| Clonazepam | Clonazepam | 83 | 16 |
| Pregabalin | Pregabalin | 82 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 81 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 32 |
| Carisoprodol | Carisoprodol | 78 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 22 |
| Cefdinir | Cefdinir | 75 | 61 |
| Estradiol | Estradiol | 72 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 11 |
| Ozempic | Semaglutide | 64 | 14 |
| Alendronate Sodium | Alendronate Sodium | 62 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 62 | 14 |
| Montelukast Sodium | Montelukast Sodium | 58 | 17 |
| Promethazine Hcl | Promethazine Hcl | 57 | 17 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Topiramate | Topiramate | 54 | suppressed |
| Glipizide Er | Glipizide | 53 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Metformin Hcl Er | Metformin Hcl | 52 | 13 |
| Ondansetron Odt | Ondansetron | 51 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 12 |
| Lansoprazole | Lansoprazole | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 15 |
| Clonidine Hcl | Clonidine Hcl | 49 | 12 |
| Famotidine | Famotidine | 49 | suppressed |
| Ibuprofen | Ibuprofen | 49 | suppressed |
| Eliquis | Apixaban | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Valsartan | Valsartan | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Methocarbamol | Methocarbamol | 41 | 11 |
| Temazepam | Temazepam | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 13 |
| Ramipril | Ramipril | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Zaleplon | Zaleplon | 17 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $322.90 · 19 records | PFIZER INC. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error